Clearmind Medicine Partners with Polyrizon for Intranasal MEAI Development

Clearmind Medicine has partnered with Polyrizon to develop a proprietary intranasal formulation of MEAI, a non-hallucinogenic neuroplastogen for CNS disorders. The collaboration aims to support Clearmind's future clinical programs by pairing MEAI with Polyrizon's intranasal delivery technology. Intranasal delivery is being pursued as a potential alternative to oral administration for CNS-active therapies, and may help bypass first-pass metabolism, support faster absorption, and reduce the dose required to achieve therapeutic effects.